Ab Initio Biotherapeutics

We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects. Our service portfolio includes mouse and rat monoclonal antibody production using hybridoma technology, human, monkey, rabbit, chicken, dog, llama and camel monoclonal antibody production using various antibody library technologies (including phage display, bacterial display and yeast display). We are also professional in conducting in depth antibody humanization and affinity maturation using phage display and DNA mutagenesis approaches. Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects. With over a decade of experience in phage display technology, Creative Biolabs can provide a series of antibody or peptide libraries that are available for licensing or direct screening. With deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. Creative Biolabs is one of the world’s leading contract organizations (CRO) that has extensive experience in preclinical drug discovery.

We provide high-end antibody discovery workflows four times faster than conventional state-of-the-art processes. We are very convinced of the quality of their work and the reliability and passion to solve any custom-related issues. We offer the customized generation and production of mouse, camelid, and human antibodies for various in vitro and in vivo applications. Founded in 2014 as an university spin-off located at the Potsdam Science Park the company is embedded in a vibrant scientific environment. To increase the efficacy of this process we developed a hyper-immunization protocol based on viral carrier proteins. In combination with selma as selection tool we provide a high end solution for the discovery of antibody producing hybridoma cells four times faster than with conventional methods. This is a very interesting feature for in vitro diagnostic applications. Creating innovative antibodies with new/era/mabs was a snap.

Abeomics is formed by a team of highly experienced scientists who also founded successful, global businesses including IMGENEX Inc., a world-class provider of Life Science reagents and contract laboratory services, and Protein Lounge, a sophisticated, interactive web database for systems biology and bioinformatics. We provide custom and contract laboratory services that facilitate your time-to-result and allow you to focus on your next steps faster. ABEOMICS provides Recombinant Biosimilar Antibodies Trastuzumab, Efalizumab, Mogamulizumab and many more.. Our marketing and business development experts can provide companion information for your studies, including consulting services for your projects, market analysis and technology assessment. Drug Discovery Screening Services | Stable Cell Line DevelopmentProtein Production | Custom Antibody Development. This large family of potential viruses has become the major pathogens for emerging respiratory disease outbreaks and can be isolated from different animal species. COVID-19 uses angiotensin-converting enzyme 2 (ACE2) as the entry receptor.

Since the DNA encoding Abcalis® antibodies is always available from the start, we can fuse the antigen binding end to many other protein domains. Every Abcalis® antibody can be acquired in every available format due to our recombinant technology. It is our mission and aspiration every single day to achieve this goal, both for a sustainable future and medical safety of this and every future generation to come. Abcalis generates anti-SARS-CoV-2 antibodies in less than 4 weeks. Abcalis is among the first companies declaring full compliance with the EU recommendations on non-animal-derived antibodies. Abcalis starts to offer cellulose-compatible antibodies for human IgG detection in lateral flow assays (LFT). Abcalis MULTICLONALS™ and monoclonals can now be purchased globally from our partners AdipoGen Life Sciences and Stratech Scientific. Abcalis has received the ECEAE Prize for Animal-Free Antibodies which was awarded for the first time.

Animab is a biotechnology company based on proprietary technology that supports livestock health. Animab integrates cutting-edge research, animal science, and biotechnology for product breakthroughs in animal health, cost-efficiencies and sustainability. Animab is founded on four patent families that cover technologies ensuring better performance, higher weight gain, better feed conversion and good physiological development with emphasis on livestock. Animab is backed by a European investor syndicate with the ambition to bring this proven concept to the market as a commercial product. Through its antibody-based approach that targets intestinal pathogens, Animab helps protect piglets during their most fragile post-weaning stage. From the production and purification of antibodies to its formulation and distribution, Animab's technology prevents intestinal bacterial colonization thanks to the direct integration with animal feed. While the antibody technology may have potential uses in various areas, Animab focuses on fighting pathogen infections in animal gastrointestinal tracts.”.

AlivaMab Biologic (AMB) sets its partners’ antibody discovery programs on the fastest and most de-risked path through discovery and development. See the most recent AlivaMab Biologics coverage in science media. Trusted by top-tier pharmaceutical and biotechnology companies, AMB delivers drug-quality, fully human antibodies on exceptional timelines. AMB rapidly and efficiently delivers truly molecularly diverse panels of antibodies, characterized for function, kinetics, and developability, and offers downstream capabilities in antibody engineering for advanced modalities, including multispecifics and CARs. This experience, combined with the use of trusted, proven technologies, including Ablexis’ AlivaMab® Mouse platforms, ensures the highest probability of success. Our technologies deliver the diversity, developability, and speed for successful development programs.